NOTE: Although this activity is no longer certified for credit, we believe that it contains important information and hope you’ll review, print or email it to a colleague.
Assessing the 5-Year Risk for Type 2 Diabetes Using Multiple Biomarkers
1.00 AMA PRA Category 1 Credits, 1.00 ANCC, 1.00 AANP
Identify at least 3 findings of the Kolberg et al study on developing a type 2 diabetes risk model utilizing a panel of serum biomarkers.
List at least 3 considerations for using this assessment tool to assess patients' 5-year risk for developing type 2 diabetes.
This educational program is conceived and credited in accordance with ACCME's Essential Areas and Policies, including the 2004 Updated Standards for Commercial Support. Pri-Med faculty hail from a variety of institutions and participate in content development, along with Pri-Med Institute's Advisory Boards and its expert review partners, the University of Wisconsin School of Medicine and Public Health and Tufts Health Care Institute. All final decisions about program content are the responsibility of Pri-Med Institute.
||AMA PRA Category 1 Credits
||Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
||Pri-Med Institute designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
||Pri-Med Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
||This activity for 1 contact hours is provided by Pri-Med Institute.
||Pri-Med Institute is approved as a provider of nurse practitioner continuing education programs by the American Academy of Nurse Practitioners. AANP Provider number 040308.
||This program has been approved for 1 contact hours of continuing education, which includes .5 hours of pharmacology.
Faculty and Editorial Board
Jay S. Skyler, MD, MACP, Diabetes Research Institute, University of Miami, Miami, Florida
M. Sue Kirkman, MD, Vice President, Clinical Affairs of the American Diabetes Association (ADA)
Kate Rouhana, MA, Pri-Med Institute
Financial Disclosure Statement(s)
Dr. Skyler serves as an adviser to, as well as a shareholder in, Tethys Bioscience. He also serves on the Boards of Amylin Pharmaceuticals, DexCom Corporation, and Merae Matrix, Inc. He is a Scientific Advisory Board Member of Patton Medical Devices and Valeritas LLC. He is on the Speakers’ Bureau of Eli Lilly & Co., Glaxo Smith-Kline, and Novo Nordisk. He provides research support to Bayhill Therapeutics, Halazyme, Inc., and Osiris Therapeutics, Inc. He serves in an advisory capacity to BD Technologies, Glaxo Smith-Kline, Ideal Life, Johnson & Johnson, MannKind Corporation, Medingo Ltd., Merck & Co., Novo-Nordisk, Salutria (Atherogenics), sanofi-aventis, Teva, and Valeritas LLC. He is a shareholder or option holder in Amylin Pharmaceuticals, DexCom Corporation, Ideal Life, MannKind Corporation, Medingo Ltd., Patton Medical Devices, and Tandem Diabetes Care.
The content collaborators at the American Diabetes Association have no financial relationships to disclose.
Dr Kirkman has no financial relationships to disclose.
Ms Rouhana has no financial relationships to disclose.
American Diabetes Association
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company, Novo Nordisk Inc., Merck & Co., Inc., Tethys Bioscience, and Daiichi Sankyo, Inc.
Instructions for Obtaining Credit:
Complete this activity. Answer the questions in the attached posttest and evaluation. Click on "claim credit" and follow the instructions to print out the credit certificate.
Computer System Requirements:
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed, nor do they necessarily reflect, those of their affiliated institutions; Pri-Med Institute; Pri-Med Institute Advisory Boards and Consultants; M|C Communications, LLC; or the American Diabetes Association.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.